6wpt
From Proteopedia
(Difference between revisions)
(One intermediate revision not shown.) | |||
Line 3: | Line 3: | ||
<StructureSection load='6wpt' size='340' side='right'caption='[[6wpt]], [[Resolution|resolution]] 3.70Å' scene=''> | <StructureSection load='6wpt' size='340' side='right'caption='[[6wpt]], [[Resolution|resolution]] 3.70Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'> | + | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WPT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WPT FirstGlance]. <br> |
- | </td></tr><tr id=' | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.7Å</td></tr> |
- | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wpt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wpt OCA], [https://pdbe.org/6wpt PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wpt RCSB], [https://www.ebi.ac.uk/pdbsum/6wpt PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wpt ProSAT]</span></td></tr> |
</table> | </table> | ||
- | <div style="background-color:#fffaf0;"> | ||
- | == Publication Abstract from PubMed == | ||
- | SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than one million infections and 73,000 deaths (1,2) . Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of a SARS survivor infected in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease. | ||
- | |||
- | Structural and functional analysis of a potent sarbecovirus neutralizing antibody.,Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D, Corti D bioRxiv. 2020 Apr 9. doi: 10.1101/2020.04.07.023903. PMID:32511354<ref>PMID:32511354</ref> | ||
- | |||
- | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
- | </div> | ||
- | <div class="pdbe-citations 6wpt" style="background-color:#fffaf0;"></div> | ||
==See Also== | ==See Also== | ||
*[[Antibody 3D structures|Antibody 3D structures]] | *[[Antibody 3D structures|Antibody 3D structures]] | ||
*[[3D structures of human antibody|3D structures of human antibody]] | *[[3D structures of human antibody|3D structures of human antibody]] | ||
- | == References == | ||
- | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: 2019-ncov]] | ||
- | [[Category: Human]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: Beltramello | + | [[Category: Beltramello M]] |
- | [[Category: Bianchi | + | [[Category: Bianchi S]] |
- | [[Category: Cameroni | + | [[Category: Cameroni E]] |
- | [[Category: Case | + | [[Category: Case JB]] |
- | [[Category: Chen | + | [[Category: Chen RE]] |
- | [[Category: Corti | + | [[Category: Corti D]] |
- | [[Category: Culap | + | [[Category: Culap K]] |
- | [[Category: Diamond | + | [[Category: De Marco A]] |
- | [[Category: Fink | + | [[Category: Diamond MS]] |
- | [[Category: Guarino | + | [[Category: Fink K]] |
- | [[Category: Havenar-Daughton | + | [[Category: Guarino B]] |
- | [[Category: Jaconi | + | [[Category: Havenar-Daughton C]] |
- | [[Category: Lanzavecchia | + | [[Category: Jaconi S]] |
- | + | [[Category: Lanzavecchia A]] | |
- | [[Category: Park | + | [[Category: Park YJ]] |
- | [[Category: Peter | + | [[Category: Peter A]] |
- | [[Category: Pinto | + | [[Category: Pinto D]] |
- | + | [[Category: Snell G]] | |
- | [[Category: Snell | + | [[Category: Spreafico R]] |
- | [[Category: Spreafico | + | [[Category: Tortorici MA]] |
- | [[Category: Tortorici | + | [[Category: Veesler D]] |
- | [[Category: Veesler | + | [[Category: Virgin HW]] |
- | [[Category: Virgin | + | [[Category: Walls AC]] |
- | [[Category: Walls | + | [[Category: Zatta F]] |
- | [[Category: Zatta | + | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + |
Current revision
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment (open state)
|
Categories: Large Structures | Beltramello M | Bianchi S | Cameroni E | Case JB | Chen RE | Corti D | Culap K | De Marco A | Diamond MS | Fink K | Guarino B | Havenar-Daughton C | Jaconi S | Lanzavecchia A | Park YJ | Peter A | Pinto D | Snell G | Spreafico R | Tortorici MA | Veesler D | Virgin HW | Walls AC | Zatta F